|
rs11615
|
|
|
0.090 |
GeneticVariation |
BEFREE |
However, no significant association was detected between rs11615 C118>T polymorphism and demographic characteristics of patients with NSCLC.
|
31245210 |
2019 |
|
rs11615
|
|
|
0.090 |
GeneticVariation |
BEFREE |
The ERCC1 rs11615 T allele and rs3212986 GG homozygosity were found to be associated with a higher risk of developing NSCLC.
|
31177178 |
2019 |
|
rs11615
|
|
|
0.090 |
GeneticVariation |
BEFREE |
The pairwise meta-analysis indicated that in terms of overall response ratio (ORR), ERCC1 (rs11615), XRCC1 (rs25487, rs1799782), and XPD (rs13181) polymorphisms are associated with the efficacy of platinum-based chemotherapy in NSCLC.
|
28520216 |
2017 |
|
rs11615
|
|
|
0.090 |
GeneticVariation |
BEFREE |
In conclusion, our study found that ERCC1 rs11615 polymorphism can influence the chemotherapy response and overall survival of NSCLC patients receiving cisplatin-based chemotherapy.
|
26045829 |
2015 |
|
rs11615
|
|
|
0.090 |
GeneticVariation |
BEFREE |
We found that polymorphisms in ERCC1 rs11615 and rs3212986 were associated with poor response to chemotherapy and shorter survival time of advanced NSCLC.
|
25366790 |
2014 |
|
rs11615
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Cox regression showed that patients carrying the rs11615 TT genotype and T allele and the rs3212986 AA genotype and A allele were significantly associated with higher risk of death from NSCLC.
|
24859833 |
2014 |
|
rs11615
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Multivariate Cox regression analysis showed that ERCC1 rs11615 AA genotype (P = 0.020) and smoking (p = 0.037) were associated with increased risks of death in early stage NSCLC patients after surgery.
|
24933103 |
2014 |
|
rs11615
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Two single nucleotide polymorphisms (SNPs) in ERCC1 gene, T19007C (rs11615) and C8092A (rs3212986), reportedly predict to affect the mRNA of ERCC1 in non-small cell lung cancer (NSCLC).
|
21553053 |
2012 |
|
rs11615
|
|
|
0.090 |
GeneticVariation |
BEFREE |
We investigated the association of three DNA repair gene polymorphisms - Asn118Asn in ERCC1 (rs11615), Lys751Gln in ERCC2 (rs13181), and Asp1104His in ERCC5 (rs17655) - with the progression-free survival of 85 patients treated with platinum-based chemotherapy after surgery for NSCLC.
|
21766907 |
2011 |
|
rs3212986
|
|
|
0.060 |
GeneticVariation |
BEFREE |
The ERCC1 rs11615 T allele and rs3212986 GG homozygosity were found to be associated with a higher risk of developing NSCLC.
|
31177178 |
2019 |
|
rs3212986
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Compared with CC genotype, AA genotype of ERCC1 rs3212986 was a high-risk factor for NSCLC (OR = 3.246; 95%CI: 1.375-7.663).
|
30453383 |
2018 |
|
rs3212986
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Cox regression showed that patients carrying the rs11615 TT genotype and T allele and the rs3212986 AA genotype and A allele were significantly associated with higher risk of death from NSCLC.
|
24859833 |
2014 |
|
rs3212986
|
|
|
0.060 |
GeneticVariation |
BEFREE |
In the Cox proportional hazards model, patients carrying the ERCC1 rs3212986 AA genotype were significantly associated with increased risk of death from NSCLC when compared with those with CC genotype as a reference variable.
|
24370899 |
2014 |
|
rs3212986
|
|
|
0.060 |
GeneticVariation |
BEFREE |
We found that polymorphisms in ERCC1 rs11615 and rs3212986 were associated with poor response to chemotherapy and shorter survival time of advanced NSCLC.
|
25366790 |
2014 |
|
rs3212986
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Two single nucleotide polymorphisms (SNPs) in ERCC1 gene, T19007C (rs11615) and C8092A (rs3212986), reportedly predict to affect the mRNA of ERCC1 in non-small cell lung cancer (NSCLC).
|
21553053 |
2012 |
|
rs2298881
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We, therefore, performed a case-control study to investigate the association of seven selected single nucleotide polymorphisms (SNPs), in genes coding for excision repair cross-complimentary group 1 (ERCC1: rs11615, rs3212986, rs2298881), nuclear factor ĸB (NFKB2: rs7897947, rs12769316), bone morphogenetic protein 4 (BMP4: rs1957860), complement receptor 1 (CR1: rs7525160) and del/ins polymorphism in the family hypoxia inducible factor 2 gene (EGLN2: rs10680577), with non-small cell lung cancer (NSCLC) risk.
|
31177178 |
2019 |
|
rs2298881
|
|
|
0.020 |
GeneticVariation |
BEFREE |
ERCC1 rs2298881C>A, an intronic SNP, is the first genetic polymorphism with functional evidence of regulating its expression, and the SNP is associated with prognosis of NSCLC.
|
26056042 |
2015 |
|
rs781163425
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We evaluated seven single-nucleotide polymorphisms of six genes CDA Lys27Gln (A/C); CDA C435T; ERCC1 C118T; XRCC3 Thr241Met (C/T); XPD Lys751Gln (A/C); P53 Arg72Pro (G/C), and RRM1 C524T in 192 chemotherapy-naive patients with advanced NSCLC treated with cisplatin/gemcitabine-based regimen by TaqMan probe-based assays with 7300 Real-Time PCR System, using genomic DNA extracted from blood samples.
|
22052224 |
2011 |
|
rs1362623672
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To evaluate the effect of genetic variations on chemotherapy and/or radiotherapy, we genotyped four single nucleotide polymorphisms (SNPs) in ATM (A60G), ERCC1 (Asn118Asn), APE1 (Asn148Glu), and iASPP (A67T), and examined their associations with treatment response among patients with advanced non-small cell lung cancer (NSCLC).
|
17222938 |
2007 |